文献速递类风湿关节炎血管炎

生物制剂或可通过抑制冠脉斑块形成与稳定高危斑块预防RA心血管事件

Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions.
PubMed 文献 · Arthritis Rheumatol · 2020-08-07

单中心观察队列纳入150例类风湿关节炎患者行冠脉CTA,101例平均6.9±0.3年后复查评估斑块进展。调整斑块负荷、Framingham-D'Agostino评分及随时间变化的DAS28-CRP后,当前使用生物制剂DMARD与较低长期CVD风险相关(OR 0.15,95%CI 0.04-0.60)。

要点

  • 当前使用生物制剂DMARD与RA患者较低长期心血管事件风险相关(OR 0.15)。
  • 生物制剂对CVD风险的保护作用仅在基线存在非钙化或低衰减斑块的患者中显著。
  • 生物制剂暴露与斑块钙化转变、低衰减斑块消退及早期动脉粥样硬化患者新斑块形成减少相关。

核心结论

  • 在RA中,生物制剂DMARD使用与降低的CVD风险、非钙化病灶的保护性钙化以及早期动脉粥样硬化患者新斑块形成可能性降低相关。

研究设计与样本

  • 单中心观察性队列研究,150例RA患者行CT血管造影评估冠状动脉粥样硬化,其中101例在平均6.9±0.3年后重复评估斑块进展;CVD事件前瞻性记录,采用Framingham-D'Agostino评分评估心血管风险,节段狭窄评分衡量斑块负荷,计算OR及95%CI。

主要发现

  • 调整节段狭窄评分、Framingham-D'Agostino评分及随时间变化的DAS28-CRP(边际结构模型)后,当前生物制剂DMARD使用与较低长期CVD风险相关(OR 0.15,95%CI 0.04-0.60)。
  • 基线存在非钙化斑块或低衰减斑块者中生物制剂使用与较低CVD风险相关(OR 0.21,95%CI 0.04-0.99;OR 0.08,95%CI 0.01-0.70),无此类斑块者中未见关联。
  • 生物制剂暴露与非钙化斑块向混合/钙化斑块转变相关(OR 4.00,95%CI 1.05-15.32)。
  • 其他冠脉节段无混合/钙化斑块的患者中,生物制剂暴露与无斑块节段新发斑块可能性降低相关(OR 0.40,95%CI 0.17-0.93),有钙化者中未见此关联;生物制剂治疗还预测低衰减斑块消退(P = 0.042)。

关键数值与推荐

  • 当前生物制剂DMARD使用与较低长期CVD风险相关:OR 0.15(95%CI 0.04-0.60)。
  • 基线有非钙化斑块者CVD风险OR 0.21(95%CI 0.04-0.99),有低衰减斑块者OR 0.08(95%CI 0.01-0.70)。
  • 非钙化向混合/钙化斑块转变OR 4.00(95%CI 1.05-15.32);无斑块节段新发斑块OR 0.40(95%CI 0.17-0.93);低衰减斑块消退P = 0.042。

临床怎么用

  • 对RA患者评估冠脉斑块特征(尤其非钙化及低衰减斑块)可能有助于识别生物制剂DMARD心血管获益更明显的人群。
  • 生物制剂DMARD治疗决策中可将冠状动脉粥样硬化早期阶段的斑块稳定与预防新斑块形成作为潜在额外获益考量。

局限性

  • 单中心观察性队列研究,样本量有限(150例,重复评估101例),可能存在残余混杂,不能直接确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether biologic disease-modifying antirheumatic drugs (DMARDs) decrease cardiovascular disease (CVD) risk in rheumatoid arthritis (RA) and whether biologic DMARDs might have a beneficial effect on coronary plaque formation or progression. METHODS: In this single-center observational cohort study, 150 patients underwent computed tomographic angiography for evaluation of coronary atherosclerosis (total, noncalcified, mixed/calcified, and low-attenuation plaque); 101 had repeat assessments within a mean ± SD of 6.9 ± 0.3 years to evaluate plaque progression. All CVD events were prospectively recorded, including cardiac death, myocardial infarction, unstable angina, revascularization, stroke, claudication, and hospitalization for heart failure. The Framingham-D'Agostino score was used to assess cardiovascular risk. The segment stenosis score was used to measure plaque burden. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. RESULTS: After adjustment for the segment stenosis score, the Framingham-D'Agostino score, and time-varying Disease Activity Score in 28 joints using the C-reactive protein level using marginal structural models, current biologic DMARD use was associated with lower long-term CVD risk (OR 0.15 [95% CI 0.04-0.60]). Noncalcified and low-attenuation plaque presence moderated the effect of biologic DMARDs on CVD risk; specifically, biologic DMARD use was associated with lower CVD risk in patients with noncalcified or low-attenuation plaque at baseline (OR 0.21 [95% CI 0.04-0.99] and OR 0.08 [95% CI 0.01-0.70], respectively), but not in those without noncalcified or low-attenuation plaque. Per-segment plaque progression analyses showed that biologic DMARD exposure was associated with transition of noncalcified to mixed/calcified plaque (OR 4.00 [95% CI 1.05-15.32]). Biologic DMARD exposure predicted a lower likelihood of new plaque forming in segments without plaque among patients without mixed/calcified plaque in other coronary segments (OR 0.40 [95% CI 0.17-0.93]), but not among those with calcification. Biologic DMARD treatment also predicted low-attenuation plaque loss (P = 0.042). CONCLUSION: Our findings indicate that in RA, biologic DMARD use is associated with reduced CVD risk, protective calcification of noncalcified lesions, and lower likelihood of new plaque formation in patients with early atherosclerosis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Karpouzas GA, Ormseth SR, Hernandez E, et al. Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions. Arthritis Rheumatol. 2020. PMID: 32319221. doi:10.1002/art.41293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。